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Summary 
Inbred strains of mice provide a model for studies of the pathogenesis of amyloid A (AA) amy- 
loidosis. All susceptible strains of mice described to date codominantly express two serum amyloid 
A  (apoSAA) isoforms, apoSAA1 and apoSAA2, of which only apoSAA2 serves as a precursor 
for amyloid fibrils. In previous studies,  we have shown that the CE/J strain,  which produces 
a single, novel apoSAA isoform, apoSAAcE/j, is amyloid resistant.  In the present study amyloid- 
resistant CE/J females were mated with amyloid-susceptible CBA/J males to produce F1 hybrid 
offspring which were then backcrossed to the parental CBA/J mouse strain.  Amyloid suscepti- 
bility was determined in 30 backcrossed mice 72 h after injection of murine amyloid enhancing 
factor and silver nitrate. ApoSAA isoforms in plasma were separated by isoelectric focusing gel 
electrophoresis and visualized after immunoblotting with anti-AA antiserum. Amyloid A fibrils 
in spleen homogenates were denatured by formic acid and AA protein was quantified by ELISA 
using anti-mouse apoSAA antibodies. Values <5 apoSAA equivalent units were considered nega- 
tive. 13 mice expressed an apoSAA1 and apoSAA2 doublet characteristic of CBA/J mice, whereas 
17 mice, expressed the apoSAAcE/j isoform codominantly with apoSAA1 and apoSAA2. The 
correlation of amyloid resistance to expression of the apoSAAcE/j isoform was absolute (17/17 
were negative; mean score 2.6  _  0.17 [standard  error of the mean] apoSAA equivalent units) 
and the correlation between amyloid susceptibility and the expression of apoSAAz/apoSAA1 was 
also striking (12/13 were amyloid positive; mean score 47.9  _+ 9.0 [standard error of the mean] 
apoSAA equivalent units (P ~0.001). This is not significantly different from the 50% segrega- 
tion of apoSAA phenotypes expected for linkage to a single gene. These results  indicate that 
a single gene governs apoSAAcE/j expression and thus confers protection against amyloid depo- 
sition even in the presence of apoSAA1 and apoSAA2 isoforms and show for the first time that 
resistance to AA amyloidosis  is a dominant trait governed by a single gene. 
myloidosis is a disease characterized by progressive fibrillar 
protein deposits in various organs. To date more than 
16 proteins have been shown to be amyloidogenic, including 
the 3-amyloid protein characteristic  of Alzheimer's disease 
(1). A common form of systemic amyloidosis is that which 
may develop secondary to chronic inflammatory diseases such 
as rheumatoid arthritis or leprosy (amyloid A [AA] amyloid- 
osis) or as a result of a genetic abnormality as in familial Medi- 
terranean  fever (2). In the latter two syndromes, fibrils are 
composed of, or derived from, an acute phase protein, serum 
amyloid A  (apoSAA). 
AA amyloidosis has been described as a biphasic process 
(3, 4) that includes a latent, preamyloid phase that may last 
for decades before amyloid fibril formation takes place. The 
pathogenesis of AA amyloidosis is not fully understood, but 
is known to involve a spectrum of factors including synthesis, 
catabolism, and structure of the precursor apoSAA, the pen- 
taxin, serum amyloid P component, and other extracellular 
matrix constituents such as proteoglycans.  The most com- 
monly used experimental model of AA amyloidosis  is one 
in which inbred strains of mice are subjected to multiple sub- 
cutaneous injections of casein or azocasein at intervals of 24 h 
or greater (5). In response to inflammatory stimulation, CBA/J 
and other amyloid-susceptible strains of mice, including A/J, 
codominantly express two major apoSAA isoforms, apoSAA1 
and apoSAA2 (6-8). Only apoSAA2 serves as a precursor for 
AA  protein,  which  is  comprised of the  first  76  NH2- 
terminal amino acids and which is the predominant com- 
ponent  of  amyloid fibrils  extracted  from  tissues  (9-11). 
ApoSAA2  is  selectively  and  more  rapidly  cleared  from 
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amyloid fibrils  in amyloid susceptible strains of mice is not 
clear.  In our hands,  most mouse strains  tested to date vary 
with respect to the duration  of the preamyloid phase with 
an induction  time ranging  between 5 d in CBA/J mice to 
>40 d in A/J mice (12).  We have postulated that,  in strains 
producing  the amyloidogenic apoSAA2 isoform,  variability 
depends on the rate of  production during the preamyloid phase 
of a poorly characterized substance called amyloid enhancing 
factor (AEF). AEF was first described as a "transfer factor" 
produced  in  donor  mice  that  accelerated the  induction  of 
amyloid in recipient  animals  (13).  Using a modification of 
the transfer model we have subsequently shown that the pre- 
amyloid phase in A/J mice can be reduced to <48 h by in- 
jecting them with AEF plus a single inflammatory  stimu- 
lus  (14). 
We have recently discovered that inbred CE/J mice, which 
do  not  express  the  amyloidogenic  apoSAA2,  but  rather  a 
single,  novel isotype, apoSAAc~/j (15) are completely resis- 
tant  to  amyloidosis  (16).  In  pilot  studies,  F1  hybrid  mice 
were produced by mating CE/J females with CBA/J males: 
F1 hybrid  offspring were then  backcrossed to  the  parental 
CE/J mouse strain.  When challenged with azocasein,  CBA/J 
mice developed amyloidosis within  10 d.  Conversely, none 
of 20 CE/J  mice,  none  of 10 F1  hybrid  CE/J  x  CBA/J 
mice, and none of 10 backcross F1  x  CE/J mice developed 
amyloidosis after 60 d  (17).  In  the  present  study,  we have 
used CBA/J  x  CE/J F1 animals to complete the reciprocal 
backcross into  the  susceptible CBA/J parental  strain. 
Materials  and Methods 
Mice.  CBA/J mice (6 wk of age) were obtained through the 
Animal Procurement  Program  of the National  Cancer Institute. 
CE/J mice (6-8 wk of age) were obtained from Jackson Laborato- 
ries, Bar Harbor, ME. All animals were housed in the Animal Re- 
search Facility at the E. N. Rogers Memorial VA Medical Center, 
Bedford,  MA,  under  standard  conditions.  These  facilities  are 
AAALAC accredited and all experimental protocols were approved 
by the VA Animal Research Subcommittee and by the IACUC of 
Boston  University  School of Medicine. 
Amyloid Induction and Quantification.  30 (CBA/J  x  CE/J) Ftx 
CBA/J backcrossed mice were given a single intraperitoneal injec- 
tion (200 #g total protein) of routine AEF (18) and a single, con- 
comitant  subcutaneous injection  of 0.5 ml of 2% AgNO3  as an 
inflammatory  stimulus.  72 h later blood samples were taken by 
cardiac puncture after induction of CO2 narcosis. The spleens were 
removed and representative samples were weighed, homogenized 
in normal saline, and AA fibrils denatured by incubation in 10% 
formic acid for 20 h at 37~  AA protein was quantified by ELISA 
using anti-mouse apoSAA antibodies (15, 19). By this technique 
scores <5 apoSAA equivalent units  are classified as negative. 
Analysis of  apoSAA lsoforms  by IEF Gel Electrophoresis.  apoSAA 
proteins were separated by IEF and visualized after immunoblot- 
ting with anti-AA antiserum as described previously (16). Briefly, 
an ultrathin  acrylamide gel was cast containing an ampholine gra- 
dient of 20% ampholines pH 3-10, 40% ampholines pH 4-6.5, 
and 40% ampholines pH 7-9 (Pharmacia LKB Biotechnology Inc., 
Piscataway, NJ) (20, 21). 20 #1 of mouse plasma was lyophilized 
and delipidated with a 2:1 mixture  of chloroform:methanol  (22). 
The protein was then resuspended in 7 M urea, 1% decyl sodium 
sulfate, and 5% 2-mercaptoethanol. After IEF, proteins were trans- 
ferred to nitrocellulose membranes. ApoSAA isoforms were detected 
with rabbit anti-mouse AA as primary antibody and an alkaline phos- 
phatase-conjugated  goat  anti-rabbit  IgG as secondary antibody. 
Results and Discussion 
After treatment with AgNO3 and AEF,  spleens  of the 17 
backcrossed mice expressing the  apoSAAcE/s  isoform were 
all negative for amyloid (mean score 2.6  _+  0.17 (SEM).  In 
contrast,  12 of 13 mice expressing only apoSAA1/apoSAA2 
were positive (mean score 47.9  _+  9.0 (SEM) (P <0.001). By 
IEF analysis, 13 of 30 mice expressed a characteristic  apoSAA, 
and apoSAA2 doublet, whereas 17 of 30 mice expressed the 
apoSAAcs/j  isoform  codominantly  with  apoSAA1  and 
apoSAA2 (Fig.  1, lane 1 ). This is not significantly different 
from the 50% segregation of apoSAA phenotypes expected 
if it were linked to a single gene. The correlation of amyloid 
resistance  to expression of the apoSAAcs/s isoform was ab- 
solute  (17/17  were  negative)  and  the  correlation  between 
amyloid susceptibility and the expression of apoSAAz paired 
with apoSAA1 was also striking  (12/13 were amyloid posi- 
tive).  These  results  indicate  that  a  single  gene  governs 
apoSAAcE/j  expression and thus confers protection  against 
amyloid deposition  even  in  the  presence  of apoSAA1  and 
apoSAA2 isoforms.  In combination with the results of our 
pilot study in which  100%  of CBA/J  x  CE/J  F,  hybrids 
were negative for amyloid deposits (Table 1), these data sup- 
port the hypothesis that  the unique amyloidogenic molec- 
ular motif ascribed to apoSAA2 protein (15) is incapable of 
overriding  the structural  properties  of the apoSAAc~/j iso- 
form in determining whether amyloid fibril formation occurs 
in vivo. 
The novel apoSAA isoform, apoSAAcE/j, in CE/J  strain 
mice has amino acid sequences characteristic  of both apoSAA1 
and apoSAA2. It is identical to apoSAA1 in the first 10 NHz- 
terminal  amino acids,  a region in which apoSAA2  has  sub- 
Figure  1.  IEF gel displaying apoSAA proteins after immunoblotting 
with anti-AA antiserum as described  in Materials and Methods. Lane 1 
shows the apoSAA1 (a), apoSAA2 (b), and apoSAAc~/j (c) isoform pat- 
tern always  found in each CBA/J x F~ backcrossed  mouse (n = 17). Lane 
2 shows the similar isoform  pattern found in parental F1 CBA/J x CE/J 
hybrids. Lane  3 shows the isoform  pattern previously  described  in CBA/J 
mice. Lane 4 shows the isoform pattern that is characteristic of CBA/J 
x  F1 backcrossed  mice of which 12 developed amyloidosis. 
2250  Linkage  of Amyloid Resistance in the Mouse to a Single, Dominant Gene Table  1.  Summary  of Studies Showing the Association of Amyloid Resistance with the apoSAAc~/j Isoform 
apoSAA  Profile 
Strain  Amyloid positive  apoSAAcE/j  apoSAAz  apoSAA,  Reference 
CBA/J  20/20  -  +  +  16 
CE/J  0/20  +  -  -  16 
F1(CBA  x  CE/J)  0/10  +  +  +  17 
FI(CBA  x  CE/J)  x  CE/J  0/6  +  -  -  17 
F~(CBA  x  CE/J)  x  CE/J  0/4  +  +  +  17 
FI(CBA  x  CE/J)  x  CBA  12/13  -  +  +  * 
Ft(CBA  x  CE/J)  x  CBA  0/17  +  +  +  * 
stitutions at positions 6  and 7 (Fig.  2).  It differs from the 
amyloidogenic apoSAAz isoform in 6 amino acid residues al- 
though it is identical to apoSAA2 at positions 75-77, the re- 
gion at which serum amyloid precursor protein is cleaved to 
yield the AA fibril protein.  It has been suggested that the 
amyloidogenic capacity of apoSAA resides in the amino acid 
residues of the NH2-terminus of the molecule (23).  Peptides 
corresponding to the first 11 amino acids of apoSAA2 but 
not apoSAA1 were capable of forming fibrils in vitro. This 
implies that the amino acid differences at positions 6 and 7 
(Val-His  in apoSAA1 compared with  Ile-Gly in apoSAA2) 
might be the critical residues in the determination of amyloid 
fibril  formation. In this regard, apoSAAcE/j  is identical to 
apoSAA1 in the first 10 amino acids but differs from both 
apoSAA1 and apoSAA2 at position  11  (Fig.  2). 
There are several  other possibilities for mechanisms by which 
the presence of apoSAAcE/j could confer resistance or pro- 
tection. First, it might interfere with the process of fibrillo- 
genesis itself, by binding a necessary cofactor or chaperone. 
AEF  (14),  proteoglycans (24),  fibronectin (25),  ot  1-anti- 
chymotrypsin, and apolipoprotein E (26) have all been aug- 
apoSAA  I 
1  2  3  4  5  6  7  8  9  I0  11 
Gly-Phe-Phe-Ser-Phe-Val-His-Glu-Ala-Phe-Gln 
apoSAA  2  Gly-Phe-Phe-Ser-Phe-Ile-Gly-Glu-Ala-Phe-G1n 
apoSAAcE/j  Gly-  Phe-  Phe-  Ser  -  Phe-Val-His-Glu-Ala-Phe-  Leu 
Figure  2.  Comparison of NHz-terminal amino acid sequences  (1-11) 
of apoSAA  isoforms. 
gested as possible modulators of fibril formation. By demon- 
strating that CE/J mice produce AEF in response to chronic 
inflammation (27), we have ruled out the possibility that an 
inherent lack of transfer factor is responsible for amyloid re- 
sistance  in  the CE/J  mouse.  A  second possibility  is  that 
apoSAAcp./j  could  alter  catabolism  of other  acute  phase 
apoSAA proteins, possibly by interactions with cell-surface 
receptors on mononuclear phagocytic cells, to prevent cleavage 
of apoSAA2 to the AA fibril.  Third, it is conceivable that 
protection does not depend on apoSAAcE/j protein per se, 
and that a "resistance" factor is closely linked to the CE/J 
type apoSAA locus on chromosome 7 and presumably in a 
cluster of 79 kb or less (7, 28). A similar configuration was 
recently shown not to be the case in the A/J strain where 
the prolonged preamyloid phase was not determined by al- 
leles at or close to the SAA locus (29). 
The availability  of murine strains that appear to be com- 
pletely resistant to amyloid induction, even in the presence 
of amyloidogenic apoSAA precursor proteins, will be invalu- 
able in answering a number of questions concerning struc- 
tural specificity of interactions of apoSAA proteins with cho- 
lesterol and/or mechanisms of cell-apoSAA recognition. The 
discovery of a single gene which is inherited as an autosomal 
codominant trait for amyloid susceptibility in the murine 
model may have important implications with respect to the 
pathogenesis of amyloidosis secondary to familial Mediterra- 
nean fever, which is also governed by a single gene (2). Fur- 
thermore, the protective effect that is associated with the mouse 
apoSAAcs/j isoform may have relevance in certain forms of 
A-B amyloidosis, e.g., Alzheimer's disease, where polymor- 
phism in one or more gene loci may accelerate or retard amyloid 
fibril deposition (30). 
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